Turn Therapeutics develops topical therapeutics for inflammatory skin diseases, wounds, and infections using its PermaFusion platform for localized drug delivery across skin and nail tissue. The approach enables stable formulations of active ingredients that act at the site of disease without broad systemic exposure. Pipeline efforts concentrate on dermatology and wound care indications where site-specific treatment provides safety or convenience benefits.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -1.2 | — |
| Q3 2025 | 0 | — | -1.9 | — |
| Q4 2025 | 0 | — | 0.3 | — |
| Q1 2026 | 0 | — | -1 | — |
| Q2 2026 | 0 | — | -5.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: PowerFleet, Inc. (AIOT), Canopy Growth Corporation (CGC), NN, Inc. (NNBR), Irenic Acquisition Corp. (IACQ), Opus Genetics, Inc. (IRD), Forafric Global PLC (AFRI)